San Diego, CA – September 17, 2015 – Objective Capital Partners, a leading middle market investment bank focused on transactions for privately held companies with enterprise values up to $250 million, is pleased to announce that it has added Dr. David Crean as a Managing Director to lead its life sciences investment banking practice.
Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital-raising activities.
According to Managing Director Trever Acers, “Over the past ten years since the firm’s inception, Objective Capital Partners has developed a highly engineered proprietary process designed to maximize transaction value. By combining Dr. Crean’s significant relationships and deep domain expertise with our proprietary process, we can provide significant value to our clients in the life sciences space.” Dr. Crean added, “I am thrilled to be part of the team and am excited to leverage my network and expertise on behalf of the Objective team.”
About David Crean
Prior to joining Objective Capital Partners, Dr. Crean served over 20 years in specialty pharmaceuticals; namely at Allergan (NYSE:AGN) and Aqua Pharmaceuticals, a private equity-backed company, prior to being sold to Almirall, SA. (BME:ALM). In these roles, Dr. Crean led transaction execution in a wide range of specialty areas including injectable and topical facial aesthetics, therapeutic skin care and movement-related neurological disorders and ophthalmology.
Dr. Crean’s pharmaceutical and biotechnology leadership experience includes serving in key leadership roles in the development and/or growth of many R&D and commercial portfolios including: BOTOX, LUMIGAN, JUVEDERM, LATISSE, ACZONE, TAZORAC, MONODOX, FLUOROPLEX, XOLEGEL and VERDESO. Concurrent with Objective, Dr. Crean leads the business development efforts for Amydis Diagnostics, Inc., an early stage diagnostic company, and serves as an Independent Board Member for Andrew Technologies, LLC, a venture-backed medical technology company.
Dr. Crean holds a Masters of Business Administration Degree with a finance concentration from Pepperdine University School of Management. Additionally, he holds a Doctorate of Philosophy Degree in Biophysics and a Masters of Science Degree in Oncology from the State University of New York at Buffalo. Dr. Crean also earned a Bachelor of Science Degree in Biology from Canisius College.
About Objective Capital
Objective Capital Partners (www.objectivecp.com) is a leading M&A investment banking firm with over 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies with annual revenues up to $250 million. Services include sale transactions, equity and debt capital raises and comprehensive advisory services. The firm uses a proprietary process to work to achieve maximum company valuation, premium pricing, and high client satisfaction rates post-sale. The firm’s industry expertise includes: life sciences, business services, software and hardware technology, aerospace/defense, IT services, healthcare services, energy services, biotech, consumer products and specialized manufacturing.